Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

J Res Med Sci · 2011 · PMC3214348 · PMID 22091259

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results of this study were similar to the previous study that showed a trend towards fewer relapse in the RRMS. 31 An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral Methotrexate (20 mg) and Interferon b-la (IFNb-la) in patients with MS; 32 44% reduction in the number of Gadolinium -enhanced lesions on MRI scan was observed during combination therapy (p = 0.02).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.